Perampanel
- Generic Name
- Perampanel
- Brand Names
- Fycompa
- Drug Type
- Small Molecule
- Chemical Formula
- C23H15N3O
- CAS Number
- 380917-97-5
- Unique Ingredient Identifier
- H821664NPK
- Background
Perampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. The FDA label includes an important black-boxed warning of serious or life-threatening behaviora...
- Indication
Perampanel is indicated for the treatment of partial-onset seizures with or without secondarily generalized seizures in epileptic patients four years of age and older. It is also indicated as an adjunct in the treatment of primary generalized tonic-clonic seizures in epileptic patients aged 12 years and older.
- Associated Conditions
- Epilepsy, Primary Generalized Tonic-Clonic Seizures, Partial-Onset Seizures
- Associated Therapies
- -
PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest
- Conditions
- Interventions
- First Posted Date
- 2024-05-07
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 52
- Registration Number
- NCT06401707
- Locations
- 🇺🇸
Zuckerberg San Francisco General Hospital, San Francisco, California, United States
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
- Conditions
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Yale University
- Target Recruit Count
- 50
- Registration Number
- NCT05915013
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Wayne State University
- Target Recruit Count
- 25
- Registration Number
- NCT05684978
- Locations
- 🇺🇸
Wayne State University, Detroit, Michigan, United States
A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic Seizures
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Eisai Korea Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT05533814
- Locations
- 🇰🇷
Eisai Site #3, Daejeon, Korea, Republic of
🇰🇷Eisai Site #10, Jeonju, Korea, Republic of
🇰🇷Eisai Site #5, Seoul, Korea, Republic of
Clinical Efficacy and Safety of Perampanel Monotherapy in the Treatment of Children With Focal Epilepsy
- Conditions
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- Yang Xinwei
- Target Recruit Count
- 280
- Registration Number
- NCT05497193
- Locations
- 🇨🇳
XI Jing Hospital, Xi'an, Shan XI, China
A Multi-center RWS of Perampanel as an add-on Treatment for Epileptic Seizures in Chinese Children
- Conditions
- Interventions
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Beijing Children's Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT05274035
- Locations
- 🇨🇳
Beijing Children's Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Jinan Children's Hospital, Jinan, Shandong, China
🇨🇳Wuhan Children's Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
A China RWS to Evaluate the Effectiveness and Safety of Perampanel as an add-on Treatment for Epileptic Seizure
- Conditions
- Interventions
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- Beijing Children's Hospital
- Target Recruit Count
- 600
- Registration Number
- NCT05257915
- Locations
- 🇨🇳
Beijing TianTan Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Beijing Children's Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Beijing University First Hospital, Beijing, Beijing, China
Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 4
- Registration Number
- NCT04650204
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
The Efficacy of Fycompa (Perampanel) in Children With Epilepsy
- Conditions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2020-10-29
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 38
- Registration Number
- NCT04608799
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Effect of Perampanel on Peritumoral Hyperexcitability in HGG
- Conditions
- Interventions
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT04497142
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.